Genentech’s Sandra Horning to Retire, Levi Garraway Named Successor

Roche subsidiary Genentech announced Monday that Sandra Horning, chief medical officer and head of global product development since 2014, will retire at the end of the year. Horning joined Genentech in 2009 as a senior vice president. Levi Garraway has been appointed Horning’s successor. Garraway recently resigned from Eli Lilly (NYSE: [[ticker:LLY]]), where he was senior vice president of oncology research and early phase development. Genentech said Garraway will start his new role on Oct. 1 and will be based at the company’s South San Francisco site.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan